NCT06719128View on ClinicalTrials.gov

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

August 25, 2025

Study Completion Date

August 25, 2025

Conditions
Hepatic InsufficiencyHealthy
Interventions
DRUG

Olomorasib

Administered orally.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

78215

American Research Corporation at Texas Liver Institute, San Antonio

92630

Orange County Research Center, Lake Forest

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06719128 - A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants | Biotech Hunter | Biotech Hunter